National University of Singapore

University of Cambridge

Singapore Health Services Pte Ltd

University of Mysore

Bangalore University

Kam Man Hui

Feng Li

Peter Edward Lobie

Vijay Kumar Pandey

Shobith Rangappa

Basappa

Alan Prem Kumar

Qing Cheng

Amudha Deivasigamani

Gautam Sethi

Jeffrey L Bidwell

Andreas Bender

Hanumantharayappa Bharathkumar

Julian Fuchs

Kanchugarakoppal Subbegowda Rangappa

Muthu Kumaraswamy Shanmugam

Krishna Bulusu

Chakrabhavi Dhananjaya Mohan

Xiaoyun Dai

The present disclosure relates to compound of structural Formula I and a method for preparing said compounds. The disclosure further relates to a method of employing the Formula I compounds for modulation of Janus kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway in cancer cells, and the corresponding use of compound of Formula I as anti-cancer agents.

Compounds as modulator of JAK-STAT pathway, methods and applications thereof

The present invention relates generally to genetic sequences exhibiting differential expression patterns in cancer tissue relative to normal tissue. The identification of differentially expressed genetic sequences permits their use as molecular markers for cancer, as early indicators of cancer progression and/or as predictive markers for a propensity or likelihood of a cancer to develop. The present invention relates particularly to genetic sequences exhibiting expression patterns up-regulated in cervical cells or associated with pre-, early- or late-onset cervical cancer relative to normal cervical cells. The genetic sequences of the present invention provide markers for early- or late-onset cervical cancer and/or a cancer related to cervical cancer. The markers of the present invention further provide potential targets for the development of therapeutic protocols for the treatment or prophylaxis of cervical or related cancer. Such therapeutic protocols are directed to inhibiting expression of the marker or inhibiting the expression product of the marker. The present invention is further directed to a method for identifying molecular markers which are useful indicators of cervical cancer and/or its progression.

Molecular markers

A method of human HLA-DR and/or Dw allotype matching comprises: (i) effecting polymerase chain reaction (PCR) amplification of a HLA-DRB gene exon 2 nucleotide sequence of a first sample of DNA; (ii) separating according to size the DNA fragments resulting from the said amplification; (iii) determining the length polymorphism of the thus separated DNA fragments; and (iv) comparing the thus-determined length polymorphism with the length polymorphism of DNA fragments resulting from PCR amplification of the said HLA-DRB gene exon 2 nucleotide sequence of a second sample of DNA.

Human leukocyte antigen typing

Growing community of inventors

Singapore, Singapore

Kam Man Hui